Search

Menu

Close

SearchConditionsDMcITPDM HomeAbout DMOCTAGAM 10% resultscITP HomePrivacy PolicyTerms of Use  Contact PfizerFind savings

Get results with 
OCTAGAM 10%

OCTAGAM 10% showed proven results in a clinical trial

In the trial, 95 adults with dermatomyositis (DM) were split into two groups. Group 1 was given OCTAGAM 10% and Group 2 was given placebo. Patients in both treatment groups could continue taking their other medications while they were part of the trial. The clinical trial looked at how patients improved in DM muscle and skin symptoms after 16 weeks.

OCTAGAM 10% helped patients achieve greater improvement in DM symptoms compared to placebo*

*Symptoms were measured on a 100-point scale as measured by the Total Improvement Score (TIS), with 0 being worsening or no improvement and 100 being the most improvement. An improvement of at least 20 points was considered minimal; at least 40 points was considered moderate; and at least 60 points was considered major.

Patient symptoms also improved sooner with OCTAGAM 10% vs placebo†

†Based on measuring median time to (at least) minimal improvement.

Patients taking OCTAGAM 10% demonstrated a greater improvement in DM skin symptoms compared to patients taking placebo

Over 16 weeks, researchers examined DM skin symptoms across the body. The score for these symptoms ranged from 0-100 with 0 being no symptoms and 100 being the most severe symptoms.

Over 16 weeks, researchers examined DM skin symptoms across the body. The score for these symptoms ranged from 0-100 with 0 being no symptoms and 100 being the most severe symptoms.

The OCTAGAM 10% group score decreased from 19.0 to 9.6 (a 9.4-point improvement)‡

The placebo group score decreased from 18.8 to 17.6 (a 1.2-point improvement)‡

‡Scores are averages. Improvement in the OCTAGAM 10% DM trial is based on scores measured at 16 weeks from baseline. DM skin symptoms were measured using modified Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) total activity score.

Most common drug-related side effects

In the clinical trial, more than 5% of patients had the following side effects:

  • Headache: 42%
  • Fever: 19%
  • Nausea: 16%
  • Vomiting: 8%
  • Chills: 7%
  • Musculoskeletal pain: 7%
  • Increased blood pressure: 6%

Getting started with
OCTAGAM 10%

View helpful info on what to
expect before, during, and after
OCTAGAM 10% infusions

Have questions about
OCTAGAM 10%?

Find answers to frequently asked questions and get connected to additional support

Looking for financial
assistance?

Learn about the OCTAGAM 10%
Co-Pay Program for eligible
patients

Patients should always ask their doctors for medical advice about adverse events.
You may report an adverse event related to Pfizer products by calling 1-800-438-1985 (US only). If you prefer, you may contact the US Food and Drug Administration (FDA) directly. The FDA has established a reporting service known as MedWatch where healthcare professionals and consumers can report problems they suspect may be associated with the drugs and medical devices they prescribe, dispense, or use. Visit www.fda.gov/MedWatch or call 1-800-FDA-1088.
OCTAGAM® is a registered trademark of Octapharma AG.
This site is intended only for US residents. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only and is not intended to replace discussions with a healthcare provider.
Pfizer

PO Box 29309

Mission, KS 66201